MedPath

Natural Supplements for Unipolar Depression

Phase 4
Completed
Conditions
Unipolar Depression
Interventions
Drug: Supplements of L-methionine, betaine and folate
Registration Number
NCT00226356
Lead Sponsor
Cambridge Health Alliance
Brief Summary

This study is being conducted to determine the clinical response rate for the regimen of L-methionine, betaine and folate for unipolar depression.

Detailed Description

The study is 6 weeks long, with 9 clinical visits. All visits will take place at our location in Massachusetts.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • DSM-IV diagnosis of a MDD or DDNOS; clinical indication for treatment of current depressive symptoms; HDS > 18; women of reproductive potential must use an acceptable method of birth control
Exclusion Criteria
  • Treatment with another psychotropic drug; history of mania or hypomania; history of bipolar illness in first-degree relatives; active homicidality; pregnant; trying to become pregnant, or nursing; unstable medical condition; current substance abuse in the past month; history of sulfa allergy

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Supplements of L-methionine, betaine and folateSupplements of L-methionine, betaine and folate-
Primary Outcome Measures
NameTimeMethod
Depressive symptoms
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Cambridge Health Alliance

🇺🇸

Cambridge, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath